SUBSCRIBE
SUBSCRIBE

Leyden Labs

NEWS
Business
Leyden Labs Aims $140 Million More at Severe Respiratory Infections
Leyden Labs secured $140 million in a Series B financing round. Combined with $40 million from a Series A round in March 2021, the company has significant funding to advance its portfolio of candidates.
January 25, 2022
 · 
3 min read
 · 
Alex Keown
BioSpace Global Roundup: Leyden Labs Secures €40 Million in Series A Financing
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
March 25, 2021
 · 
6 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Press Releases
Leyden Labs Secures €30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses
October 2, 2025
 · 
5 min read
Press Releases
Leyden Labs Publishes New Data Confirming Potential of Intranasal Antibody Approach
April 8, 2025
 · 
5 min read
Press Releases
Leyden Labs Raises $70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other Viruses
January 9, 2025
 · 
3 min read
Press Releases
Leyden Labs Appoints Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer
September 12, 2024
 · 
3 min read
Drug Development
Leyden Labs’ Intranasal PanFlu Antibody Enters the Clinic
April 19, 2023
 · 
3 min read
Genetown
Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses
January 25, 2022
 · 
4 min read
Genetown
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
January 18, 2022
 · 
3 min read
Business
Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory Viruses
July 21, 2021
 · 
3 min read
Deals
Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital
March 25, 2021
 · 
3 min read